sp. PL1-032A was isolated from Pearse Lakes, Western Australia. The sequenced genome consists of a single chromosome (2,705,688 bp) with a GC content of 47.2%. The isolation of sp. PL1-032A contributes to the collection of culturable extremophiles and offers potential insight into the Pearse Lakes biome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11385443 | PMC |
| http://dx.doi.org/10.1128/mra.00361-24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complete genome sequence of a sp. PL1-032A isolated from the pink hypersaline Pearse Lakes, Rottnest Island, Western Australia.
Microbiol Resour Announc
September 2024
Bioplastic Innovation Hub, Food Futures Institute, Murdoch University, Murdoch, Western Australia, Australia.
sp. PL1-032A was isolated from Pearse Lakes, Western Australia. The sequenced genome consists of a single chromosome (2,705,688 bp) with a GC content of 47.
View Article and Find Full Text PDFComplete genome sequence of sp. PL1-037 isolated from the pink hypersaline Pearse Lakes, Rottnest Island, Western Australia.
Microbiol Resour Announc
August 2024
Bioplastic Innovation Hub, Food Futures Institute, Murdoch University, Murdoch, Western Australia, Australia.
sp. PL1-037 was isolated from Pearse Lakes, Rottnest Island, Western Australia. The sequenced completed genome for PL1-037 is composed of a single chromosome (2,804,934 bp) with a GC content of 47.
View Article and Find Full Text PDFComplete genome sequence of a sp. PL1-022 isolated from the pink hypersaline Pearse Lakes, Rottnest Island, Western Australia.
Microbiol Resour Announc
August 2024
Bioplastic Innovation Hub, Food Futures Institute, Murdoch University, Murdoch, Western Australia, Australia.
sp. PL1-022 was isolated from Pearse Lakes, Western Australia. The sequenced genome consists of a chromosome (3,140,198 bp; 48.
View Article and Find Full Text PDFAdding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Lancet
June 2024
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. Electronic address:
Article Synopsis
- A clinical trial called RADICALS-HD studied the effects of adding short-course androgen deprivation therapy (ADT) to postoperative radiotherapy in patients with localized prostate cancer after surgery.
- It involved 1480 patients, examining how ADT impacts metastasis-free survival compared to radiotherapy alone, and measured outcomes like distant metastasis and overall survival.
- The trial aimed to see if combining ADT with radiotherapy could improve the 10-year metastasis-free survival rate, potentially increasing it from 80% to 86%.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Lancet
June 2024
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK. Electronic address:
Article Synopsis
- The study investigates the effectiveness and optimal duration of androgen deprivation therapy (ADT) combined with postoperative radiotherapy for patients with localized prostate cancer following radical prostatectomy.
- A randomised controlled trial, RADICALS-HD, compared short-course ADT (6 months) to long-course ADT (24 months) among participants who met specific criteria, including PSA levels and absence of metastatic disease.
- The primary outcome measured was metastasis-free survival, with the trial aiming to determine if longer ADT duration leads to better survival rates, involving over 1,500 patients from 2008 to 2015.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!